Clinical evaluation of a rapid and sensitive detection system for epidermal growth factor receptor (EGFR) mutations named PNA-LNA PCR clamp

3072 Background: Gefitinib, an inhibitor of the tyrosine kinase activity of EGFR,was introduced in the treatment of advanced non-small lung cancers (NSCLC). The responsiveness to gefitinib has been reported to closely link to the presence of EGFR mutations. Clinical samples contain many normal cells in addition to cancer cells. Direct DNA sequencing and single strand conformational polymorphism (SSCP) can only detect one mutant cell in at most 5...